Clinical Trial Detail

NCT ID NCT02708641
Title A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients 60 With AML
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Michael Boyiadzis
Indications

acute myeloid leukemia

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.